SCHEMBL5458072

SCHEMBL5458072

O=C(O)c1cc2ccccc2nc1-c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.48
TSHR P16473 1/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
PDE10A Q9Y233 3/20 0.46
CDC7 O00311 1/20 0.46
DBF4 Q9UBU7 1/20 0.46
PDGFRB P09619 1/20 0.45
PDGFRA P16234 1/20 0.45
MAPK10 P53779 1/20 0.45
MAPK14 Q16539 1/20 0.45
HTT P42858 1/20 0.45
IKBKB O14920 1/20 0.44
CSNK2A2 P19784 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912410 0.90 PDE10A (0.56) DHODHSMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL8807038 0.85 SMN1; SMN2 (0.56) SMN1; SMN2TSHRKDM4EALDH1A1HPGD
SCHEMBL529972 0.84 MEN1 (0.57) DHODHSMN1; SMN2TSHRNPC1RAB9A
SCHEMBL1339563 0.83 DHODH (0.52) DHODHSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL27720177 0.80 PDE10A (0.56) DHODHSMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL5457550 0.78 RAD51 (0.40) DHODHSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL327089 0.78 IKBKB (0.63) DHODHSMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL30499579 0.78 IKBKB (0.63) DHODHSMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL1902570 0.77 LMNA (0.47) DHODHSMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL8521039 0.76 NPC1 (0.63) DHODHSMN1; SMN2TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2007-08-16 US disclosed
EP-0366189-A2 Novel antimicrobial lactam-quinolones Norwich Eaton Pharmaceuticals, Inc. (US) 1990-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy HIF1AN, HIF1A, HYOU1 DHODH 46/4885SMN1; SMN2 4159/4885TSHR 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.